Saturday, Jun 06, 2020 | Last Update : 07:18 AM IST

73rd Day Of Lockdown

Maharashtra77793336812710 Tamil Nadu2725614901223 Delhi250049898659 Gujarat18609126671155 Rajasthan98627104213 Uttar Pradesh92375439245 Madhya Pradesh87622772377 West Bengal68762768355 Bihar4452212028 Karnataka4320161057 Andhra Pradesh4112252971 Haryana3281112324 Telangana31471587105 Jammu and Kashmir3142104835 Odisha247814819 Punjab2415204347 Assam19894434 Kerala158969015 Uttarakhand115328610 Jharkhand7642975 Chhatisgarh6781892 Tripura6221730 Himachal Pradesh3691636 Chandigarh3022225 Goa126570 Manipur124110 Puducherry90330 Nagaland8000 Arunachal Pradesh3710 Meghalaya33131 Mizoram1710 Sikkim200

Human bodies get resistant to antibiotics for treating harmful bacteria

Published : Oct 22, 2019, 9:43 am IST
Updated : Oct 22, 2019, 9:43 am IST

Studies reveal that human body resists antibiotics for treating harmful bacteria for multiple stomach conditions.

The research was presented today at UEG Week Barcelona 2019. (Photo: ANI)
 The research was presented today at UEG Week Barcelona 2019. (Photo: ANI)

Washington: A recent study has discovered that the human body starts getting resistant to antibiotics for treating harmful bacteria for a variety of stomach conditions, and the changes have more than doubled in 20 years.

Antibiotic resistance occurs when bacteria develop the ability to survive exposure to medications designed to kill or halt their growth. It is one of the greatest threats to global health today, causing more than 750,000 deaths every year and, without urgent action, this number is expected to rise dramatically in the future.

The research was presented today at UEG Week Barcelona 2019. The study analysed 1,232 patients from 18 countries across Europe, investigated resistance to antibiotics regularly taken for 'helicobacter pylori' (H. pylori) infection, a harmful bacterium associated with gastric ulcer, lymphoma, and gastric cancer.

Presenting the study, lead researcher Prof Francis Megraud explained: " 'H pylori infection is already a complex condition to treat, requiring a combination of medications. With resistance rates to commonly used antibiotics such as clarithromycin increasing at an alarming rate of nearly one per cent per year, treatment options for 'H pylori' will become progressively limited and ineffective if novel treatment strategies remain undeveloped."

'H pylori' is one of the most common bacterial infections in humans and is estimated to be present in one-half of the world's population. 'H pylori' leads to inflammation of the stomach lining, namely gastritis, which can result in peptic ulcers.

Underlining the severity of the situation, in 2017, the World Health Organisation (WHO) identified clarithromycin-resistant 'H pylori' as a high priority bacterium for antibiotic research and development.

The survey also found that the rates of primary clarithromycin resistance in 'H pylori' were highest in southern Italy (39.9 per cent), Croatia (34.6 per cent) and Greece (30 per cent), aligning with previous reports that predict that both Italy and Greece will have the highest number of deaths due to antimicrobial resistance amongst EU members by 20507.

The high levels of resistance exhibited in these countries have been attributed to the overconsumption of antibiotics for conditions including cold and flu, and a lack of institutional support for antibiotic resistance containment strategies.

"The findings of this study are certainly concerning, as 'H pylori' is the main cause of peptic disease and gastric cancer," commented Mario Dinis-Ribeiro, president of the European Society of Gastrointestinal Endoscopy. "The increasing resistance of 'H pylori' to a number of commonly-used antibiotics may jeopardise prevention strategies."

Tags: antibiotics, bacteria, gastric cancer